| 前收市價 | 2.2500 |
| 開市 | 2.3000 |
| 買盤 | 1.5000 |
| 賣出價 | 2.5500 |
| 拍板 | 40.00 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 2.2500 - 2.3000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2.26k |
ZacksWall Street Analysts Think Immunovant (IMVT) Could Surge 68.63%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 68.6% in Immunovant (IMVT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
ZacksZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
